Credit Suisse Ag Ventyx Biosciences, Inc. Transaction History

Credit Suisse Ag

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 08, 2024	BUY	$2.08 - $31.18 $10,859 - $162,790	5,221 Added 13.49%	43,918 $108,000
Q3 2023 Nov 13, 2023	BUY	$29.8 - $40.3 $54,087 - $73,144	1,815 Added 4.92%	38,697 $1.34 Million
Q2 2023 Aug 11, 2023	BUY	$28.53 - $39.55 $650,426 - $901,660	22,798 Added 161.87%	36,882 $1.21 Million
Q1 2023 May 10, 2023	BUY	$29.51 - $46.65 $35,943 - $56,819	1,218 Added 9.47%	14,084 $471,000
Q4 2022 Feb 13, 2023	BUY	$24.16 - $36.38 $307,774 - $463,444	12,739 Added 10030.71%	12,866 $421,000
Q3 2022 Nov 10, 2022	BUY	$12.64 - $38.7 $1,390 - $4,257	110 Added 647.06%	127 $4,000
Q2 2022 Aug 12, 2022	BUY	$11.95 - $18.75 $203 - $318	17 New	17 $0

125

52.9M

35.3K

83K

Ticker VTYX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,527,200
Market Cap $127M
Description
Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis...

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

Stay updated on Credit Suisse Ag with notifications on news.